AstraZeneca Sees Positive Phase 3 Trial Data for Imfinzi Cancer Treatment
29 Juni 2023 - 4:15PM
Dow Jones News
By Chris Wack
AstraZeneca said a Phase III trial showed its Imfinzi durvalumab
plus Imjudo demonstrated a sustained, clinically meaningful overall
survival benefit at four years for patients with unresectable
hepatocellular carcinoma who had not received prior systemic
therapy and were not eligible for localized treatment.
The pharmaceutical company said that at four years of follow-up,
the data show that a single priming dose of Imjudo added to Imfinzi
reduced the risk of death by 22% compared with sorafenib.
An estimated 25.2% of patients treated were alive at four years
versus 15.1% for those treated with sorafenib.
The safety profile of the Imjudo/Imfinzi regimen was consistent
with the known profiles of each medicine, and no new safety signals
were observed with longer follow-up. Serious treatment-related
adverse events, defined as Grade 3 or 4 and including death, were
experienced by 17.5% of patients treated with the regimen versus
9.6% of patients treated with sorafenib.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 29, 2023 10:00 ET (14:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024